PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $111,260 | -36.8% | 10,198 | -51.2% | 0.01% | -7.1% |
| Q3 2022 | $176,000 | -83.9% | 20,887 | -84.9% | 0.01% | -84.4% |
| Q2 2022 | $1,095,000 | +98.0% | 138,395 | +492.4% | 0.09% | +95.7% |
| Q1 2022 | $553,000 | +30.7% | 23,360 | -2.2% | 0.05% | -9.8% |
| Q3 2021 | $423,000 | – | 23,876 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |